Phaseline

Companies › Taysha Gene Therapies

Taysha Gene Therapies: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 1; Neurology, Psychiatry; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TSHA-102
recombinant, non-replicating, self-complementary AAV9 vector encoding miniMECP2 gene, deli
MECP2Phase 3Rett SyndromeNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06152237TSHA-102Phase 1Rett SyndromePsychiatryNov 2028
NCT07480564TSHA-102Phase 3Rett SyndromeNeurologyJun 2031
NCT05606614TSHA-102Phase 3Rett SyndromeNeurologyJun 2031

From the company's SEC filings

Cash of $455m on 2026-06-30; operating cash outflow about $165m a year; runway about 33 months at that burn, to Apr 2029; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MECP2 (1)

Companies with the same targets

Ionis Pharmaceuticals Neurogene

Companies built like this

Neurogene Dyne Therapeutics Stoke Therapeutics Capricor ProofPilot

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.